UCBUCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB). For more information, please visit www.ucb.com

UCB RSS Channel

Display # 
Title Published Date
UCB to focus on core business in India 02 April 2015
UCB and Biogen Idec enter agreement to commercialize multiple sclerosis and hemophilia therapies in Asia 30 January 2014
Multimillion pound investment in UK life sciences research and development 11 December 2013
Cimzia® (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis 30 September 2013
UCB announces regulatory filings for Cimzia® (certolizumab pegol) 20 February 2013
Accelerating focus on the patient 14 February 2013
UCB announces third research collaboration with Harvard University 10 October 2012
UCB half year results 2012: on track for growth 01 August 2012
UCB expands in Brazil 30 May 2012
UCB marks World Parkinson's Disease Day with new Parkinson's Well-Being Map™ 11 April 2012
Neupro® approved by U.S. FDA for Parkinson's disease and Restless Legs Syndrome 03 April 2012
Positive top-line result for UCB's Cimzia® in psoriatic arthritis 16 February 2012

Digest World Pharma Newsletter

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]